In Vitro Diagnostics (IVD) is central to precision medicine, enabling disease screening, diagnosis, and therapeutic monitoring. While mass spectrometry (MS) remains the dominant platform for metabolomics, Nuclear Magnetic Resonance (NMR) spectroscopy has emerged as a robust complementary technology due to its high reproducibility, quantitative reliability, and non-destructive nature. This review systematically evaluates the role of NMR-based metabolomics in clinical IVD, focusing on applications in oncology, cardiovascular disease, and neurology. This study critically examines technical strengths and limitations and identifies key barriers to clinical translation, particularly in standardization, data harmonization, and regulatory validation. Finally, we propose a framework to facilitate the integration of NMR into routine clinical workflows.
Nicholson J, Holmes E, Kinross J, et al., 2012, Metabolic Phenotyping in Clinical and Surgical Environments, Nature, 491(7424): 384-392.
Dona A, Jiménez B, Schäfer H, et al., 2014, Precision High-Throughput Proton NMR Spectroscopy of Human Urine, Serum, and Plasma for Large-Scale Metabolic Phenotyping, Analytical Chemistry, 86(19): 9887-9894.
Emwas A, Roy R, McKay R, et al., 2019, NMR Spectroscopy for Metabolomics Research, Metabolites, 9(7): 123.
Wishart, D, 2008, Quantitative Metabolomics Using NMR, TrAC Trends in Analytical Chemistry, 27(3): 228-237.
Gowda N, Raftery D, 2019, NMR-Based Metabolomics, Humana.
Otvos J, Mora S, Shalaurova I, et al., 2011, Clinical Implications of Discordance Between Low-density Lipoprotein Cholesterol and Particle Number, Journal of Clinical Lipidology, 5(2): 105-113.
European Parliament and Council of the European Union, 2017, Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU, 117: 176-332.